Status:

COMPLETED

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Lead Sponsor:

Baxalta now part of Shire

Conditions:

Hemophilia A

Eligibility:

All Genders

Up to 6 years

Phase:

PHASE2

PHASE3

Brief Summary

The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study is a pharmacokinetic ...

Eligibility Criteria

Inclusion

  • Subject is less than 6 years of age
  • Severe or moderately-severe hemophilia A as defined by a baseline factor VIII level \<= 2%, documented at screening or on the basis of historical data (e.g., at hemophilia diagnosis)
  • Documented medical history of at least 50 exposure days for treatment with all other factor VIII products
  • Subject's parent or legally authorized representative has provided informed consent

Exclusion

  • Detectable inhibitor to factor VIII measured in the screening sample by the local or central hemostasis laboratory
  • History of inhibitor to factor VIII at any time prior to screening
  • Subject has any one of the following laboratory abnormalities at the time of screening:
  • platelet count \< 100,000/mm3
  • hemoglobin concentration \< 10 g/dL (100 g/L)
  • serum creatinine \> 1.5 times the ULN for age
  • total bilirubin \> 2 times the ULN for age
  • Subject has an inherited or acquired hemostatic defect other than hemophilia A (e.g., platelet dysfunction secondary to uremia, liver failure, von Willebrand's Disease)
  • Subject has known hypersensitivity to RECOMBINATE rAHF
  • Subject is currently participating in another investigational drug study or has participated in any clinical study involving an investigational drug within 30 days of study entry
  • Subject is identified by the investigator as being unable or unwilling to cooperate with study procedures

Key Trial Info

Start Date :

June 7 2002

Trial Type :

INTERVENTIONAL

End Date :

January 4 2005

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00157040

Start Date

June 7 2002

End Date

January 4 2005

Last Update

April 27 2021

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Children´s Hospital Los Angeles

Los Angeles, California, United States, 90027

2

Emory University, Department of Pediatrics

Atlanta, Georgia, United States, 30322

3

Children´s Memorial Hospital

Chicago, Illinois, United States, 60614

4

Comprehensive Bleeding Disorders Center

Peoria, Illinois, United States, 61614